Article title: Emerging drugs for the treatment of hereditary angioedema due to C1-inhibitor deficiency
Authors: Zanichelli, A., Montinaro, V., Triggiani, M., Arcoleo, F., Visigalli, D., & Cancian, M.
Journal: EXPERT OPINION ON EMERGING DRUGS
DOI: https://doi.org/10.1080/14728214.2022.2105834
When this article was published online there were some errors which are now corrected and they are listed below.
In section 3, the first bulletin has been updated as “a plasma-derived C1-INH for subcutaneous use (twice weekly) approved in the US (Haegarda®), in Europe (Berinert s.c.®), and in other countries [14]”
Section heading 3.1 is corrected as S.c. pdC1-INH (Haegarda®/Berinert s.c.®)
The fist statement in section 3.1. is corrected as “Plasma-derived C1-inhibitor administered intravenously for on demand therapy was approved at a different dosage for subcutaneous use in long-term prophylaxis.”
In table 1, the first value in last column is corrected as 38-40% (16 weeks).
The table 2 caption is corrected as “Table 2. Countries where Haegarda®/Berinert s.c.® TakhzyroTM, and OrladeyoTM are licensed, together with the year when they were approved. Data were gathered from Pharmaprojects [https://pharmaintelligence.informa.com/products-and-services /clinical-planning/pharmaprojects].”